Minovia Therapeutics has earned FDA Fast Track and Rare Pediatric Disease designations for MNV-201, its pioneering cell therapy targeting Pearson Syndrome—an ultra-rare, fatal mitochondrial disease in children. Currently in Phase 2 trials, MNV-201 leverages Minovia’s proprietary mitochondrial augmentation technology and now moves closer to market with regulatory momentum and the potential for a valuable priority review voucher. Minovia previously announced a Business Combination Agreement (BCA) with Launch One Acquisition Corp. (Nasdaq: LPAA). Following the expected closing of the transaction contemplated by this BCA, projected for late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol. See the full release for further details and disclosures.

Jupiter Neurosciences (Nasdaq: JUNS) has introduced Nugevia™ PWR, a mitochondrial optimization supplement built on its pharmaceutical-grade JOTROL™ platform, designed to enhance energy, endurance, and recovery. Launching this fall, PWR targets the booming $8 trillion longevity market and marks a strategic move to monetize Jupiter's clinical science in high-margin consumer health products.

Trinity Biotech (Nasdaq: TRIB) has reached a critical profitability inflection point, projecting Adjusted EBITDA-positive operations in Q2 2025 and forecasting sustained positive cash flow starting Q3. This marks a major achievement in its turnaround strategy, as the company pivots toward growth with a leaner cost base, expanding product rollouts, and progress on its next-gen CGM solution targeting the $13B diabetes market.

XTI Aerospace (Nasdaq: XTIA) has successfully completed a key FAA technical review of the TriFan 600’s structural design, marking a significant step toward type certification for its pioneering VTOL aircraft. The company’s ongoing collaboration with the FAA underscores its commitment to advancing the TriFan 600—a high-speed, 1,000-mile-range xVTOL—toward commercial readiness.